749
Views
12
CrossRef citations to date
0
Altmetric
Review

CD38 as an Immunomodulator in Cancer

, , &
Pages 2853-2861 | Received 24 Apr 2020, Accepted 24 Jul 2020, Published online: 28 Aug 2020
 

Abstract

CD38 is a transmembrane glycoprotein that is widely expressed in a variety of human tissues and cells, especially those in the immune system. CD38 protein was previously considered as a cell activation marker, and today monoclonal antibodies targeting CD38 have witnessed great achievements in multiple myeloma and promoted researchers to conduct research on other tumors. In this review, we provide a wide-ranging review of the biology and function of the human molecule outside the field of myeloma. We focus mainly on current research findings to summarize and update the findings gathered from diverse areas of study. Based on these findings, we attempt to extend the role of CD38 in the context of therapy of solid tumors and expand the role of the molecule from a simple marker to an immunomodulator.

Author contributions

The concept and design was conducted by Y Li. Y Li and R Yang drafted the manuscript and contributed equally. Critical revision of the manuscript for important intellectual content was conducted by L Chen and S Wu. S Wu provided the funding support. All authors read and approved the final manuscript.

Financial & competing interests disclosure

This work was supported by the Shanghai Municipal Natural Science Foundation (no. 18ZR1430500). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This work was supported by the Shanghai Municipal Natural Science Foundation (no. 18ZR1430500). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.